| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Molnupiravir-d7 targets the same molecular entity as non-deuterated Molnupiravir: the viral RNA-dependent RNA polymerase (RdRp). Molnupiravir is metabolized to its active form, EIDD-1931 triphosphate, which is incorporated into viral RNA by RdRp, leading to error catastrophe through the accumulation of lethal mutations in the viral genome.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[3].
Molnupiravir-d7 itself is an analytical standard with no biological activity of its own. The non-deuterated parent, Molnupiravir, has broad-spectrum antiviral activity against influenza virus and multiple coronaviruses, including SARS-CoV-2, MERS-CoV, and SARS-CoV. In vitro, it inhibits SARS-CoV-2 replication with EC50 values in the low micromolar range. |
| ln Vivo |
Molnupiravir-d7 is not a therapeutic agent. The non-deuterated parent, Molnupiravir, is an orally bioavailable prodrug with proven in vivo efficacy. In animal models (mice, ferrets), Molnupiravir reduces viral load in lung tissue, prevents transmission, and improves survival. It has received emergency use authorization and full approval in multiple countries for the treatment of COVID-19.
|
| Enzyme Assay |
Not applicable. As a deuterated internal standard, Molnupiravir-d7 is not used in primary enzyme/receptor assays. The non-deuterated parent is a well-characterized RdRp inhibitor. Standard RdRp inhibition assays involve measuring RNA synthesis by recombinant SARS-CoV-2 RdRp complex in the presence of N4-hydroxycytidine triphosphate (the active form) to assess inhibition.
|
| Cell Assay |
Not applicable. Molnupiravir-d7 is not used directly in cell-based assays. The non-deuterated parent is evaluated in antiviral assays: Vero E6 or other susceptible cells are infected with SARS-CoV-2 at MOI 0.01-0.1, treated with serial dilutions of Molnupiravir (0.1-100 microM) for 24-48 hours, and viral replication is measured by RT-qPCR, plaque reduction, or CPE assay to determine EC50.
|
| Animal Protocol |
For in vivo studies, Molnupiravir-d7 is spiked into biological samples (plasma, tissue homogenates) as an internal standard prior to sample processing for LC-MS analysis. The non-deuterated parent is administered orally to animal models or patients (e.g., 800 mg twice daily for 5 days in humans). Standard protocols for testing in vivo efficacy involve administering Molnupiravir to SARS-CoV-2-infected mice or ferrets by oral gavage.
|
| ADME/Pharmacokinetics |
Molnupiravir-d7 is a stable isotopically labeled compound intended for use as an internal standard for the quantification of Molnupiravir by LC-MS. The non-deuterated parent, Molnupiravir (EIDD-2801), has a molecular weight of 329.31. It is orally bioavailable with an elimination half-life of approximately 1-2 hours in humans. It is extensively metabolized to its active form, EIDD-1931.
|
| Toxicity/Toxicokinetics |
Molnupiravir-d7 is not intended for therapeutic use; its toxicity is not assessed directly. The non-deuterated parent, Molnupiravir, has a favorable safety profile in clinical trials. Common adverse effects include diarrhea (2%), nausea (1%), and dizziness (1%). Preclinical toxicology studies have shown no genotoxicity or carcinogenicity at therapeutic doses. It is contraindicated during pregnancy (potential fetal harm).
|
| References |
|
| Additional Infomation |
Molnupiravir-d7 is a research-grade isotopically labeled internal standard. Its non-deuterated parent drug, Molnupiravir (Lagevrio), is an FDA-approved prescription medicine for the treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease. It is the first orally available direct-acting antiviral for COVID-19. This deuterated product is for laboratory research use in analytical method development and pharmacokinetic studies, not for human administration.
|
| Molecular Formula |
C13H12D7N3O7
|
|---|---|
| Related CAS # |
Molnupiravir;2492423-29-5
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
